AzTrials
AzTrials

DiabetesProDiabetNCT04069611

Non Surgical Therapy of Periodontitis in Diabetes Patients: the Adjunctive Use of Probiotics

A study testing Probiotic and Scaling and root planing in people with Diabetes and Periodontitis, run by Universidad Complutense de Madrid at 1 site in Spain.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

The aim of this study is to evaluate the clinical and microbiological performance of a probiotic formulation (Sunstar GUM Periobalance) as adjunctive to non-surgical periodontal therapy in patients with diabetes. Read more about this study

Who is it for?
Ages 18 years and olderHealthy volunteers can take part
Conditions the study is for
Diabetes, Periodontitis
What is being tested?
Probiotic and Scaling and root planing
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
40 participants
Where
1 siteSpain
Study dates
30 Jan 2020to 31 Dec 2023
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • Healthy volunteers accepted
  • Adult, Older adult

Who may be able to join

  • Patients with diagnosed diabetes, for at least 1 year.
  • Presence of a minimum of 18 teeth.
  • Untreated stages II and III periodontitis with radiographic evidence of generalized alveolar bone loss higher than 30%, and presence of at least one pocket with probing pocket depth (PPD) higher than 5 mm per quadrant with bleeding on probing (BOP).

Who cannot join

  • Subgingival instrumentation within 12 months before baseline examination.
  • Use of antibiotics in the three months prior to the study.
  • Use of other probiotic products in the month prior the study.
  • Systemic diseases that could affect the course of periodontitis or its treatment such as immunological disorders, excluding diabetes.
  • Ongoing drug therapy influencing the evaluated clinical parameters (non-steroid inflammatory drugs, etc.).
  • Compromised medical conditions requiring prophylactic antibiotic therapy (e.g. patients with valvular prostheses, patients with previous history of bacterial endocarditis, congenital heart diseases like shunts or heart transplant recipients who developed valvular heart disease)
  • Pregnancy.
  • Stage IV periodontitis, or acute periodontal conditions.

Trial locations and contacts

1 site in 1 country.

Eduardo Montero, MSc contact

+34 630138408

eduardomonterosolis@ucm.es

Spain1 site, 1 recruiting
  • Faculty of Odontology

    Madrid, 28040

    Eduardo Montero, MSc, +34 630138408, eduardomonterosolis@ucm.es

    Recruiting

Other trials in Spain

About this study

The aim of this study is to evaluate the clinical and microbiological performance of a probiotic formulation (Sunstar GUM Periobalance) as adjunctive to non-surgical periodontal therapy in patients with diabetes. The null hypothesis is that the adjunctive use of this probiotic formulation would not have any additional benefit over scaling and root planning in the number of residual pockets or in the microbiological impact of the treatment. Conversely, the alternative hypothesis is that the adjunctive use of this formulation would improve the clinical results of non-surgical periodontal therapy when compared to scaling and root planing alone, through a modification of the subgingival biofilm composition.

Read the detailed description

Diabetes patients will be consecutively selected among those attending the Faculty of Odontology, University Complutense (Madrid, Spain). Patients fulfilling the required criteria will be invited to participate in the study, will be informed on the study purposes, and will be invited to sign and IRB approved informed consent.The study will be designed as a doubled-blind, placebo controlled, parallel, randomized clinical trial with a 6-month follow-up. The patients will be examined for clinical parameters and microbiological sampling, and randomised into two different groups.The following study visits will be scheduled:

Screening visit Potential patient eligibility will be based on the inclusion/exclusion criteria already presented. Patients will be informed about their periodontal condition and treatment needs. Patients willing to participate in the study will be given additional information about the study and upon signing a consent form, they will be appointed for the graduate clinic of Periodontology.

Baseline visit Patients will undergo a comprehensive oral and periodontal examination. Full-mouth clinical measurements of PPD and clinical attachment level (CAL) will be taken at 6 sites per tooth, excluding third molars, and will be rounded to the nearest millimetre using a UNC-15 probe (Hu-Friedy, Chicago, IL, USA). Panoramic radiographs and/or full-mouth periapical radiographs will also be taken, as standard procedures of the postgraduate clinic. Microbiological samples will be taken. The patient smoking history will be recorded and participants will be categorized as: current smokers (those who smoked at least one cigarette per day); never smokers (those who had never smoked in their life); and former smokers (those who had stopped smoking at least 1 year previously). Other relevant aspects of the medical history will be also collected, including the evaluation of the glycated haemoglobin (HbA1c) levels by means of standard laboratory procedures.

Treatment visits Subjects will receive non-surgical periodontal therapy in the form of full-mouth SRP, in two consecutive days, in combination with 0.12% chlorhexidine (Gum Chlorhexidine Oral Rinse, Etoy, Switzerland) application by means of rinsing prior to and at the end of each SRP session. All patients will receive standardized oral hygiene instructions, including the use of a manual toothbrush (GUM® Activital Toothbrush), and interdental brushers (GUM® Trav-ler and GUM® Soft Picks). Instructions will be periodically reinforced.

Immediately after oral hygiene instructions, patients will be randomly allocated to the test or control groups. One investigator before patient recruitment will generate the randomization sequence by blocks. Random assignment into two groups will be carried out with the use of a computer program. Containers will be designed to maintain examiner blinding. The patients will be randomly allocated, with the help of a computer, in two groups:

  • Test group: Subjects in the test group will take two probiotic lozenges per day for 3 months (one in the morning and one in the afternoon after brushing their teeth), starting after the last session of SRP. Lozenges will contain L. reuteri (2 x 108 colony forming units/tablet of strains ATCC 55730 and ATCC PTA 5289; Sunstar GUM Periobalance).
  • Placebo group: Subjects assigned to the placebo group will take lozenges exactly like the test ones but without bacteria.

Follow up visits after 3 and 6 months Follow up visits will have the objective to monitor the clinical and microbiological changes in the periodontal condition and to evaluate the bacterial re-colonization pattern in the subgingival niche. This phase will include two recall visits, at which clinical measurements will be repeated and microbiological samples will be collected. Oral hygiene will be reinforced. Glycated haemoglobin levels will be assessed.

Being tested
Probiotic, Placebo, Scaling and root planing
Medical subject headings
Diabetes Mellitus, Periodontitis

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • ProbioticOther

    Subjects in the test group will take two probiotic lozenges per day for 3 months (one in the morning and one in the afternoon after brushing their teeth), starting after the last session of SRP. Lozenges will contain L. reuteri (2 x 108 colony forming units/tablet of strains ATCC 55730 and ATCC PTA 5289; Sunstar GUM Periobalance).

  • PlaceboOther

    Subjects assigned to the placebo group will take lozenges exactly like the test ones but without bacteria.

  • Scaling and root planingProcedure or surgery

    Also called SRP

    Mechanical debridement with US and curettes of hard and soft plaque deposits

Study groups in NCT04069611
Study groupRoleWhat they receive
Test GroupExperimentalSubjects in the test group will receive scaling and root planing, plus the take two probiotic lozenges per day for 3 months (one in the morning and one in the afternoon after brushing their teeth), starting after the last session of SRP. Lozenges will contain L. reuteri (2 x 108 colony forming units/tablet of strains ATCC 55730 and ATCC PTA 5289; Sunstar GUM Periobalance).
Receives: Other: Probiotic; Procedure: Scaling and root planing
Control GroupPlacebo comparatorSubjects assigned to the placebo group will receive scaling and root planing, and will take lozenges exactly like the test ones but without bacteria.
Receives: Other: Placebo; Procedure: Scaling and root planing

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Probing Pocket Depth (PPD)

    Change in Probing Pocket Depth (PPD)

    Measured: Baseline, 3 and 6 months

Secondary outcomes (3)
  1. Residual Pockets (PPD>4m )

    Percentage of residual pockets

    Measured: Baseline, 3 and 6 months

  2. Bleeding on Probing (BOP)

    Changes in bleeding on probing

    Measured: Baseline, 3 and 6 months

  3. Patient Satisfaction

    Patient satisfaction as determined by visual analogue scales (min:0; max:10; 0 indicates worst patient satisfaction, while 10 indicates maximum satisfaction)

    Measured: Baseline, 3 and 6 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted28 Aug 2019
  2. Study start30 Jan 2020
  3. Primary completion30 Jun 2023 (estimated)
  4. Study completion31 Dec 2023 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Quadruple blind
Who is masked
Participant, Care provider, Investigator, Outcomes assessor
Enrolment
40 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04069611
Sponsor's protocol ID
19/101-R_X
Acronym
ProDiabet
Status last verified
May 2022
First submitted
23 Aug 2019
Last updated
1 Jun 2022
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Publications

  • Bujaldon R, Montero E, Gamonal JD, Abuelo A, Marin MJ, Iniesta M, Sanz M, Herrera D. Use of the Probiotic Limosilactobacillus reuteri as an Adjunct to Subgingival Instrumentation in the Treatment of Periodontitis Patients With Diabetes: A Randomised Clinical Trial. J Clin Periodontol. 2026 Jan;53(1):26-36. doi: 10.1111/jcpe.70035. Epub 2025 Sep 17.

    PubMed 40958659

Questions about this trial

What is this clinical trial studying?

A study testing Probiotic and Scaling and root planing in people with Diabetes and Periodontitis, run by Universidad Complutense de Madrid at 1 site in Spain.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 1 Jun 2022. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Spain. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Eduardo Montero, MSc (+34 630138408, eduardomonterosolis@ucm.es), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Probing Pocket Depth (PPD) (time frame: Baseline, 3 and 6 months). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT04069611, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 1 Jun 2022.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in